Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
Recruiting · NCT06937034 · Observational (researchers observe without assigning treatment) · Lead sponsor: AbbVie
View the official record on ClinicalTrials.gov →What this trial is about
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- \- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.
Where it is running
4 locations listed.
- Medisch Spectrum Twente /ID# 276695 - Enschede, Overijssel, Netherlands
- Karolinska University Hospital Solna /ID# 277116 - Solna, Stockholm County, Sweden
- Medizinische Universitaet Graz /ID# 278569 - Graz, Styria, Austria
- Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720 - Timișoara, Timiș County, Romania